WO2009069610A1 - 縮合インダン化合物 - Google Patents

縮合インダン化合物 Download PDF

Info

Publication number
WO2009069610A1
WO2009069610A1 PCT/JP2008/071370 JP2008071370W WO2009069610A1 WO 2009069610 A1 WO2009069610 A1 WO 2009069610A1 JP 2008071370 W JP2008071370 W JP 2008071370W WO 2009069610 A1 WO2009069610 A1 WO 2009069610A1
Authority
WO
WIPO (PCT)
Prior art keywords
nmda receptor
compound
antagonistic activity
indane compound
fused indane
Prior art date
Application number
PCT/JP2008/071370
Other languages
English (en)
French (fr)
Inventor
Satoshi Hayashibe
Shingo Yamasaki
Nobuyuki Shiraishi
Hiroaki Hoshii
Takahiko Tobe
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/741,307 priority Critical patent/US8211907B2/en
Priority to JP2009543802A priority patent/JP5251885B2/ja
Priority to CA2706171A priority patent/CA2706171C/en
Priority to ES08853617T priority patent/ES2391235T3/es
Priority to SI200830759T priority patent/SI2221296T1/sl
Priority to AU2008330653A priority patent/AU2008330653B2/en
Priority to CN2008801180038A priority patent/CN101878201B/zh
Priority to PL08853617T priority patent/PL2221296T3/pl
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Priority to MX2010005928A priority patent/MX2010005928A/es
Priority to EP08853617A priority patent/EP2221296B1/en
Priority to BRPI0819795A priority patent/BRPI0819795B8/pt
Priority to KR1020107011747A priority patent/KR101497747B1/ko
Priority to DK08853617.2T priority patent/DK2221296T3/da
Publication of WO2009069610A1 publication Critical patent/WO2009069610A1/ja
Priority to ZA2010/03112A priority patent/ZA201003112B/en
Priority to IL205551A priority patent/IL205551A/en
Priority to HRP20120944AT priority patent/HRP20120944T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

【課題】NMDA受容体拮抗剤として有用な化合物を提供する。 【解決手段】本発明者らは、NMDA受容体に対する拮抗作用を有する化合物について検討した結果、本発明に係る縮合インダン化合物が優れたNMDA受容体拮抗作用を有することを確認し、本発明を完成させた。本発明に係る縮合インダン化合物は、NMDA受容体に対する優れた拮抗作用を有し、アルツハイマー病、脳血管性認知症、パーキンソン病、難治性鬱病、注意欠陥・多動性障害、偏頭痛等の予防及び／又は治療剤の有効成分として使用することができる。
PCT/JP2008/071370 2007-11-28 2008-11-26 縮合インダン化合物 WO2009069610A1 (ja)

Priority Applications (16)

Application Number Priority Date Filing Date Title
MX2010005928A MX2010005928A (es) 2007-11-28 2008-11-26 Agentes antihelminticos y su uso.
JP2009543802A JP5251885B2 (ja) 2007-11-28 2008-11-26 縮合インダン化合物
EP08853617A EP2221296B1 (en) 2007-11-28 2008-11-26 Fused indane compound
SI200830759T SI2221296T1 (sl) 2007-11-28 2008-11-26 Kondenzirana indanska spojina
AU2008330653A AU2008330653B2 (en) 2007-11-28 2008-11-26 Fused indane compound
CN2008801180038A CN101878201B (zh) 2007-11-28 2008-11-26 稠合茚满化合物
PL08853617T PL2221296T3 (pl) 2007-11-28 2008-11-26 Skondensowany związek indanowy
US12/741,307 US8211907B2 (en) 2007-11-28 2008-11-26 Fused indane compound
CA2706171A CA2706171C (en) 2007-11-28 2008-11-26 Fused indane compound
ES08853617T ES2391235T3 (es) 2007-11-28 2008-11-26 Compuesto de indano condensado
BRPI0819795A BRPI0819795B8 (pt) 2007-11-28 2008-11-26 compostos de indano fundidos e seus usos no tratamento de doenças relacionadas ao receptor nmda, bem como composição farmacêutica compreendendo os mesmos
KR1020107011747A KR101497747B1 (ko) 2007-11-28 2008-11-26 축합 인단 화합물
DK08853617.2T DK2221296T3 (da) 2007-11-28 2008-11-26 Kondenserede indanforbindelser
ZA2010/03112A ZA201003112B (en) 2007-11-28 2010-05-04 Fused indane compound
IL205551A IL205551A (en) 2007-11-28 2010-05-05 Compressed indan compounds, pharmaceuticals containing them and their uses
HRP20120944AT HRP20120944T1 (hr) 2007-11-28 2012-11-20 Kondenzirani spoj indana

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-307753 2007-11-28
JP2007307753 2007-11-28

Publications (1)

Publication Number Publication Date
WO2009069610A1 true WO2009069610A1 (ja) 2009-06-04

Family

ID=40678506

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/071370 WO2009069610A1 (ja) 2007-11-28 2008-11-26 縮合インダン化合物

Country Status (21)

Country Link
US (1) US8211907B2 (ja)
EP (1) EP2221296B1 (ja)
JP (1) JP5251885B2 (ja)
KR (1) KR101497747B1 (ja)
CN (1) CN101878201B (ja)
AU (1) AU2008330653B2 (ja)
BR (1) BRPI0819795B8 (ja)
CA (1) CA2706171C (ja)
CY (1) CY1113634T1 (ja)
DK (1) DK2221296T3 (ja)
ES (1) ES2391235T3 (ja)
HR (1) HRP20120944T1 (ja)
IL (1) IL205551A (ja)
MX (1) MX2010005928A (ja)
PL (1) PL2221296T3 (ja)
PT (1) PT2221296E (ja)
RU (1) RU2451671C2 (ja)
SI (1) SI2221296T1 (ja)
TW (1) TWI422578B (ja)
WO (1) WO2009069610A1 (ja)
ZA (1) ZA201003112B (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9469601B2 (en) 2012-12-04 2016-10-18 Pierre Fabre Medicament Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113234036B (zh) * 2021-05-12 2023-07-14 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006033318A1 (ja) 2004-09-21 2006-03-30 Astellas Pharma Inc. 環状アミン誘導体又はその塩
WO2006094602A1 (de) 2005-03-04 2006-09-14 Merck Patent Gmbh Indane

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK12293D0 (da) * 1993-02-02 1993-02-02 Novo Nordisk As Heterocykliske forbindelser og deres fremstilling og anvendelse
US5574060A (en) * 1993-08-12 1996-11-12 The United States Of America As Represented By The Department Of Health And Human Services Selective inhibitors of biogenic amine transporters
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006033318A1 (ja) 2004-09-21 2006-03-30 Astellas Pharma Inc. 環状アミン誘導体又はその塩
WO2006094602A1 (de) 2005-03-04 2006-09-14 Merck Patent Gmbh Indane

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
BARDGETT ME; SCHULTHEIS PJ; MCGILL DL; RICHMOND RE; WAGGE JR: "Magnesium deficiency impairs fear conditioning in mice", BRAIN RES, vol. 1038, 2005, pages 100 - 6
BEAL M. F., FASEB J., vol. 6, 1992, pages 3338 - 3344
BHATTACHARYA S. ET AL.: "Synthesis and stereochemical...pyrrole derivatives", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, vol. 1, 1984, pages 5 - 13 *
CHEMBIOCHEM, vol. 5, no. 4, 2004, pages 508 - 518
DITZLER K., ARZNEIMITTELFORSCHUNG, vol. 41, 1991, pages 773 - 780
EIDE P. K., PAIN, vol. 58, 1994, pages 347 - 354
FISHER K., J. PAIN SYMPTOM MANAGE., vol. 20, 2000, pages 358 - 373
HERESCO-LEVY U.; JAVITT D. C., EURO. NEUROPSYCHOPHARMACOL., vol. 8, 1998, pages 141 - 152
HEWITT D. J., CLIN. J. PAIN, vol. 16, 2000, pages 73 - 79
HOLLMANN M.; HEINEMANN S., ANNU. REV. NEUROSCI., vol. 17, 1994, pages 31 - 108
JOURNAL OF COMPUTATIONAL CHEMISTRY, vol. 14, no. 8, 1993, pages 934 - 943
LINO M., J. PHYSIOL., vol. 424, 1990, pages 151 - 165
MAIER C., PAIN, vol. 103, 2003, pages 277 - 283
MAITI S. B. ET AL.: "Role of remote heteroatoms ...tetrahydropyridines", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, vol. 3, 1988, pages 611 - 621 *
MAURICE T; PRIVAT A: "SA4503, a novel cognitive enhancer with a receptor agonist properties, facilitates NMDA receptor- dependent learning in mice", EUR J PHARMACOL, vol. 328, 1997, pages 9 - 18
MEGURO H., NATURE, vol. 3, no. 57, 1992, pages 70 - 74
MORIYOSHI K., NATURE, vol. 354, 1991, pages 31 - 37
MORRIS R. G., NATURE, vol. 319, 1986, pages 774 - 776
OZAWA S., PROG. NEUROBIOL., vol. 54, 1998, pages 581 - 618
PALMER GC; HARRIS EW; RAY R; STAGNITTO ML; SCHMIESING RJ., ARCH INT PHARMACODYN THER., vol. 317, May 1992 (1992-05-01), pages 16 - 34
PARCELL R. F. ET AL.: "The preparation of tetrahydropyridines from enamines and imines", JOURNAL OF ORGANIC CHEMISTRY, vol. 28, no. 12, 1963, pages 3468 - 3473 *
PARSONS C. G., NEUROPHARMACOL., vol. 38, 1999, pages 735 - 767
PROG. MED., vol. 5, 1985, pages 2157 - 2161
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS, vol. 10, no. 2, 1991, pages 118 - 125
REISBERG B., N. ENGL. J. MED., vol. 348, 2003, pages 1333 - 1341
RIEDERER P., LANCET, vol. 338, 1991, pages 1022 - 1023
See also references of EP2221296A4
TETRAHEDRON LETTERS, vol. 42, no. 29, 2001, pages 4919 - 4922
TETRAHEDRON, vol. 58, no. 21, 2002, pages 4225 - 4236
TSIEN J. Z., CELL, vol. 87, 1996, pages 1327 - 1338

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9469601B2 (en) 2012-12-04 2016-10-18 Pierre Fabre Medicament Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs
US9687459B2 (en) 2012-12-04 2017-06-27 Pierre Fabre Medicament Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs

Also Published As

Publication number Publication date
JPWO2009069610A1 (ja) 2011-04-14
IL205551A (en) 2015-05-31
CN101878201B (zh) 2012-09-05
CY1113634T1 (el) 2016-06-22
TWI422578B (zh) 2014-01-11
EP2221296A1 (en) 2010-08-25
US8211907B2 (en) 2012-07-03
AU2008330653B2 (en) 2012-08-16
MX2010005928A (es) 2010-06-15
CN101878201A (zh) 2010-11-03
BRPI0819795A2 (pt) 2015-05-26
KR101497747B1 (ko) 2015-03-04
IL205551A0 (en) 2010-12-30
CA2706171C (en) 2013-10-08
KR20100091995A (ko) 2010-08-19
PL2221296T3 (pl) 2013-01-31
HRP20120944T1 (hr) 2012-12-31
BRPI0819795B1 (pt) 2019-10-15
AU2008330653A1 (en) 2009-06-04
RU2451671C2 (ru) 2012-05-27
BRPI0819795B8 (pt) 2021-05-25
EP2221296A4 (en) 2011-04-27
JP5251885B2 (ja) 2013-07-31
RU2010126202A (ru) 2012-01-10
DK2221296T3 (da) 2012-09-24
US20100267695A1 (en) 2010-10-21
TW200936568A (en) 2009-09-01
EP2221296B1 (en) 2012-09-05
PT2221296E (pt) 2012-11-23
ZA201003112B (en) 2011-07-27
ES2391235T3 (es) 2012-11-22
CA2706171A1 (en) 2009-06-04
SI2221296T1 (sl) 2012-10-30

Similar Documents

Publication Publication Date Title
WO2007019439A3 (en) Block copolymer compositions and uses thereof
WO2008076348A8 (en) Crystalline solid rasagiline base
WO2007014930A3 (de) Polyammonium-polysiloxancopolymere
WO2005079756A3 (en) Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
WO2006127941A3 (en) Amorphous cinacalcet hydrochloride and preparation thereof
WO2007022306A3 (en) Hover-buttons for user interfaces
WO2007051062A3 (en) Substituted dihydropyridines and methods of use
MX2015011778A (es) Combinacion de farmaco.
WO2013185082A3 (en) Inhibitors of bruton's tyrosine kinase
WO2008128028A3 (en) Solifenacin compositions
WO2009025876A8 (en) Crystalline forms of erlotinib hcl and formulations thereof
HK1172845A1 (en) Novel pharmaceutical formulations against drug misuse
PL2079446T3 (pl) Preparat paliperidonu o przedłużonym uwalnianiu
WO2008070072A3 (en) Carvedilol forms, compositions, and methods of preparation thereof
NZ610526A (en) Deuterium enriched rasagiline
IL183383A0 (en) Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
WO2013138568A8 (en) Liver x receptor modulators
WO2012019106A3 (en) Compounds for use in modulating the nmda receptor
WO2010058926A3 (ko) 생강 추출물 또는 쇼가올을 포함하는 약학 조성물
WO2010115125A3 (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
WO2007029087A3 (en) Controlled release multiple unit formulations
WO2006091836A8 (en) Formulations of ladostigil tartrate
EP2137127A4 (en) NOVEL PROCESSES FOR THE PRODUCTION OF 5-EPA-BETA-2-ISOPROPYL-6,10-DIMETHYL-SPIRO [4.5] DECA-2,6-DIEN-8-ONE AND 2-ISOPROPYL-6,10-DIMETHYL spiro [4.5] deca-1,6-dien-8-ONE
CA124321S (en) Mixer for viscous materials
WO2009026257A3 (en) Methods and compositions for controlling the bioavailability of poorly soluble drugs

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880118003.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08853617

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009543802

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12741307

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 205551

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008330653

Country of ref document: AU

Ref document number: 12010501013

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2706171

Country of ref document: CA

Ref document number: 1790/KOLNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008853617

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107011747

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/005928

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008330653

Country of ref document: AU

Date of ref document: 20081126

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010126202

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0819795

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100525